Related Experiment Video
Updated: Jul 2, 2026
16:40
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis
Gabriel Yeap1, Hritvik Jain2, Nandan Patel2
1Newcastle University Medical School, United Kingdom.
Current Problems in Cardiology
|June 30, 2026
Summary
Implantable cardioverter-defibrillators (ICDs) in cardiac sarcoidosis (CS) reduced mortality and transplantation but increased heart failure and arrhythmias. Real-world data shows mixed outcomes, requiring cautious interpretation due to potential biases.
Area of Science:
- Cardiology
- Electrophysiology
- Sarcoidosis Research
Background:
- Cardiac sarcoidosis (CS) poses a risk of sudden cardiac death.
- Implantable cardioverter-defibrillators (ICDs) are utilized for prevention, but real-world effectiveness is debated.
- Treatment-selection bias can influence observed outcomes in CS patients.
Purpose of the Study:
- To evaluate the real-world effectiveness of ICDs in patients with cardiac sarcoidosis.
- To assess the impact of ICD implantation on mortality, cardiac events, and healthcare utilization.
- To address uncertainties regarding ICD efficacy in CS, considering potential biases.
Main Methods:
- Retrospective cohort study using the TriNetX Global Collaborative Network.
- Propensity-score matching (1:1) balanced 4,554 adult CS patients (2,277 per cohort).
- Primary composite endpoint: all-cause mortality, heart failure exacerbation, cardiac transplantation, ventricular arrhythmia.
Main Results:
- ICD use was linked to reduced all-cause mortality (RR 0.83) and cardiac transplantation (RR 0.66).
- Higher risks observed for heart failure exacerbation (RR 1.06) and ventricular arrhythmia (RR 1.70) in ICD recipients.
- ICD recipients showed increased heart failure diagnoses (RR 1.11) and rehospitalisations (RR 1.18).
Conclusions:
- ICD implantation in cardiac sarcoidosis is associated with decreased mortality and transplantation rates.
- Findings suggest increased morbidity and healthcare utilization alongside survival benefits.
- Results must be interpreted cautiously due to potential selection bias and differential surveillance in real-world data.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...